AKT1 and breast cancer: In this scenario, the combination of a copper chelator will deplete copper and, in turn, suppress ERK and AKT pathways to sensitize NF‐κB inhibitors, as validated in different subtypes of breast cancer cells, xenografted tumors, diverse of subtypes of patients’ organoids and MMTV‐PyMT mouse mammary cancer.